

FIG. 5. Effects of rifampicin (10 μ M) and MKC-963 (0.25 μ M) on CYP3A4 mRNA (A) and activity of testosterone 6 β -hydroxylation in primary human hepatocyte cultures (B). Total RNA was extracted, and CYP3A4 and β -actin mRNA levels were measured by real-time PCR methods as described under *Materials and Methods*; then, CYP3A4 mRNA was normalized to β -actin and compared with that of a vehicle control. The mean absolute ratio for the control hepatocytes was 0.051 ± 0.02 (A). For measurement of CYP3A4 activity, testosterone was incubated with intact hepatocytes and metabolite was analyzed as described under *Materials and Methods*; then, CYP3A4 activities were compared with those of a vehicle control. The mean activity of control hepatocytes was 2.3 ± 0.7 pmol/min/ 10^5 cells (B). Results are expressed as means \pm S.D. of three experiments.

enzyme(s) of P450 mainly responsible for the metabolism of MKC-963 in humans. As shown in Fig. 6A, MKC-963 was metabolized by CYP3A4 extensively, by 2D6 moderately, and by CYP1A2 to some extent. However, when the contribution of individual P450 enzymes to the overall metabolic clearance of MKC-963 was estimated by P450 contents in human liver microsomes, approximately 90% of the MKC-963 metabolism in human liver microsomes was estimated to be attributable to CYP3A4 (Fig. 6B).

Discussion

The results of the *in vitro* study showed that MKC-963 increased CYP3A4 mRNA expression level and activity of testosterone 6 β -hydroxylation to extents similar to those observed with rifampicin in primary human hepatocytes (Fig. 5). In addition, approximately 90% of the MKC-963 metabolism in human liver microsomes was estimated to be attributable to CYP3A4 (Fig. 6B). These findings suggest that MKC-963 is a potent inducer of CYP3A4, which catalyzes the metabolism of MKC-963 itself. These *in vitro* findings are in good agreement with the results of the clinical study showing that the urinary excretion ratio of 6 β -OHF and F, a marker of CYP3A4 induction, increased significantly (Fig. 4) and that AUC and C_{max} of MKC-963 decreased dramatically after repeated oral administration of the compound to healthy volunteers (Table 1). Therefore, these findings suggest that MKC-963 is a relatively potent autoinducer of CYP3A4 in humans. Moreover, the findings also suggest that *in vitro* studies using primary human hepatocytes coupled with cDNA-expressed P450 enzymes would have been useful to predict or assess the autoinductive character of MKC-963 in the preclinical study.

In the present study, we used 0.25 μ M MKC-963 since C_{max} of MKC-963 was 0.29 μ M when 120 mg of MKC-963 was administered orally to human volunteers (Fig. 2). The concentration of rifampicin was also set at 10 μ M because it is almost the same as C_{max} of rifampicin after oral administration of 450 to 600 mg in patients with tuberculosis (Smith, 2000). At that dose, interaction of rifampicin with a number of drugs has been reported (Holtbecker et al., 1996; Villikka et al., 1999; Riditid et al., 2002). Under these conditions, the effect of MKC-963 on CYP3A4 in the primary culture of human hepatocytes was comparable to the effect of rifampicin, suggesting that MKC-963 is a potent inducer of CYP3A4, similar to rifampicin even *in vivo*.




FIG. 6. Metabolic clearance of MKC-963 in microsomes from insect cells expressing P450 enzymes (50 pmol/ml) (A) and the contributions (percentage) of each P450 enzyme to the total clearance of MKC-963 in five P450 enzymes corrected by the P450 contents in native human liver microsomes as described under *Materials and Methods* (B). MKC-963 (2 μ M) was incubated in the presence of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 for 0, 5, 15, and 30 min, at 37°C. Each value is the mean \pm S.D. of triplicate assays.

This assumption is supported by the *in vivo* observation that MKC-963 increased urinary excretion ratios of 6 β -OHF and F to an extent similar to that reported previously for rifampicin (Ohnhaus et al., 1989; Kovacs et al., 1998; Tran et al., 1999). Therefore, the concentration of the test compound used in the study on human hepatocytes appears to be an important factor for assessing the potential to induce CYP3A4 *in vivo* (Smith, 2000). In fact, it has been reported that thiazolidinediones, including troglitazone, pioglitazone, and rosiglitazone, showed the potential to induce CYP3A4 in human hepatocytes but that only troglitazone showed drug-drug interactions due to the induction of CYP3A4 *in vivo* (Sahi et al., 2003). Although the mechanism remains unknown, the authors speculated that the concentrations of pioglitazone and rosiglitazone do not reach concentrations sufficient to induce CYP3A4 in *in vivo* situations (Sahi et al., 2003). In a preclinical study, however, the actual concentrations of test compounds in plasma or other human organs are generally unknown. Thus, prediction of concentrations of the test compound in plasma or other human organs by animal scale-up (Mitsuhashi et al., 1990; Izumi et al., 1996) or by extrapolation of *in vitro* clearance obtained from human liver microsomes, human hepatocytes, or cDNA-expressed P450s to *in vivo* clearance in humans (Iwatsubo et al., 1997; Ito et al., 1998) appears to be essential to predict the ability of the test compound to induce P450 in *in vivo* situations.

Although the results of the present study clearly showed the induction of CYP3A4 after repeated oral administration of MKC-963, there were some differences in the time courses of changes in the indicators of induction. There was some delay in changes in the urinary ratio of 6 β -OHF and F (Fig. 4) compared with those of the plasma concentrations of MKC-963 at 1 h and 2 h after administration (Fig. 3). As shown in Fig. 3, the plasma concentrations of MKC-963 decreased dramatically on the second day after starting repeated oral administration of MKC-963, whereas the urinary ratios of 6 β -OHF and F did not show a remarkable change on day 2 but showed a considerable change on day 5 (Fig. 4). The reason for this difference in the time

courses of these indicators is unknown, but it may be due to the difference in the involvement of intestinal CYP3A4 in the metabolism of MKC-963. CYP3A4 has been reported to be expressed in small intestinal epithelial cells (Watkins et al., 1987; Kolars et al., 1992) as well as in hepatic parenchymal cells (Guengerich et al., 1986; Shimada et al., 1994). Intestinal CYP3A4 has recently been suggested to be a major factor in determining the extent of first-pass metabolism and, hence, oral bioavailability of drugs (Hall et al., 1999). Because MKC-963 was administered orally in the present study, plasma concentration of MKC-963 should be affected by the induction of CYP3A4 in the small intestine. Although we do not know whether MKC-963 induces CYP3A4 in the small intestine 1 day after oral administration, Kolars et al. (1992) reported that rifampicin induces small intestinal CYP3A4 mRNA within 24 h. Therefore, it is conceivable that induction of intestinal CYP3A4 by MKC-963 occurred very rapidly, and reduced the bioavailability of MKC-963 and decreased its plasma concentration within 2 days after starting drug administration. In contrast, it has been reported that the formation of 6 β -OHF is primarily mediated by the liver and that intestinal metabolism plays a minor role (Galteau and Shamsa, 2003). Therefore, it is possible that the induction of CYP3A4 in the liver is slower than that in the small intestine and that change in the urinary excretion ratio of 6 β -OHF and F was therefore delayed compared with that of plasma concentration of MKC-963 after repeated oral administration. In support of this speculation, half-maximal changes in 6 β -OHF/F have been reported to be achieved 2 to 3 days after rifampicin administration (Ohnhaus et al., 1989).

It should be noted that hepatocytes used in this study were derived from one donor; therefore, CYP3A4 induction may have been less remarkable if other livers with low levels of CYP3A4 were used in the present study. In this case, it is possible that metabolism by CYP2D6 and CYP1A2 could be a predominant route, and autoinduction of MKC-963 metabolism may not be as remarkable as that observed in the present study.

Finally, CYP3A5 may also be involved in the autoinduction of MKC-963 metabolism. This is because substrate specificities of CYP3A5 and CYP3A4 are similar and overlapped (Wrighton et al., 1990). In addition, CYP3A5 has been reported to be induced by rifampicin in primary human hepatocytes (Zhuo et al., 2004). However, both the catalytic activity and specific content of CYP3A5 in the human liver or small intestine are much lower than those of CYP3A4 (Wrighton et al., 1990; Rodrigues, 1999). Furthermore, the extent of induction of CYP3A5 by rifampicin in human hepatocytes is less than that of CYP3A4 (Zhuo et al., 2004). In addition, primer sets of CYP3A4 used in the present study were specific for CYP3A4 and do not recognize CYP3A5. Therefore, it seems that the contribution of CYP3A5 to the autoinductive nature of MKC-963, if any, is much smaller than that of CYP3A4.

In summary, in vivo findings suggesting autoinduction of MKC-963 metabolism prompted us to reevaluate the autoinductive nature of the compound using primary human hepatocytes and cDNA-expressed human P450 enzymes. The results showed that MKC-963 increased CYP3A4 mRNA expression level and activity of testosterone 6 β -hydroxylation to extents similar to those observed with rifampicin in primary human hepatocytes. In addition, approximately 90% of the MKC-963 metabolism in human liver microsomes was estimated to be attributable to CYP3A4. These findings are in good agreement with the clinical study. Therefore, in vitro studies using human hepatocytes coupled with cDNA-expressed human P450s appear to be useful for assessing the autoinductive nature of compounds under development before starting clinical studies.

References

- Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. *Ann Pharmacother* 32:554–563.
- Donato MT, Castell JV, and Gómez-Lechón MJ (1995) Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. *Drug Metab Dispos* 23:553–558.
- Donato MT, Herrero E, Gómez-Lechón MJ, and Castell JV (1993) Inhibition of monooxygenase activities in human hepatocytes by interferons. *Toxicol In Vitro* 7:481–485.
- Galteau MM and Shamsa F (2003) Urinary 6 β -hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. *Eur J Clin Pharmacol* 59:713–733.
- Guengerich FP, Martin MV, Beaune PH, Krenners P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. *J Biol Chem* 261:5051–5060.
- Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. *Drug Metab Dispos* 27:161–166.
- Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. *Drug Metab Dispos* 24:1121–1123.
- Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacol Rev* 50:387–412.
- Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. *Pharmacol Ther* 73:147–171.
- Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. *J Pharmacol Exp Ther* 277:1630–1641.
- Jerling M, Huan BL, Leung K, Chu N, Abdallah H, and Hussein Z (2005) Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. *J Clin Pharmacol* 45:422–433.
- Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992) Identification of rifampin-inducible P450III_{A4} (CYP3A4) in human small bowel enterocytes. *J Clin Invest* 90:1871–1878.
- Kovacs SJ, Martin DE, Everitt DE, Patterson SD, and Jorkasky DK (1998) Urinary excretion of 6 β -hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. *Clin Pharmacol Ther* 63:617–622.
- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Klierer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* 102:1016–1023.
- Li AP, Kaminsky DL, and Rasmussen U (1995) Substrates of human hepatic cytochrome P450 3A4. *Toxicology* 104:1–8.
- Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, and Kobayashi T (1990) Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. *Cancer Chemother Pharmacol* 27:20–26.
- Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* 27:1350–1359.
- Ohnhaus EE, Breckenridge AM, and Park BK (1989) Urinary excretion of 6 β -hydroxycortisol and the time course measurement of enzyme induction in man. *Eur J Clin Pharmacol* 36:39–46.
- Prueksaritanont T, Ma B, and Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A and not CYP2D6. *Br J Clin Pharmacol* 56:120–124.
- Riditid W, Wongnawa M, Mahathanatrakul W, Punyo J, and Sunbhanich M (2002) Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. *Clin Pharmacol Ther* 72:505–513.
- Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping. *Biochem Pharmacol* 57:465–480.
- Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, and Sinz MW (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. *Drug Metab Dispos* 31:439–446.
- Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 270:414–423.
- Smith DA (2000) Induction and drug development. *Eur J Pharm Sci* 11:185–189.
- Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, and Martin DE (1999) Morning spot and 24-hour urinary 6 β -hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. *J Clin Pharmacol* 39:487–494.
- Villikka K, Kivistö KT, and Neuvonen PJ (1999) The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. *Clin Pharmacol Ther* 65:377–381.
- Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. *J Clin Invest* 80:1029–1036.
- Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450III_{A5} (HLP3). *Mol Pharmacol* 38:207–215.
- Zhuo X, Zheng N, Felix CA, and Blair LA (2004) Kinetics and regulation of cytochrome P450-mediated topoisomerase metabolism. *Drug Metab Dispos* 32:993–1000.

Address correspondence to: Dr. Kan Chiba, Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8675, Japan. E-mail: kchiba@p.chiba-u.ac.jp

Expert Opinion

1. Introduction
2. General features
3. Sites of polymorphisms and allelic frequency in different ethnic populations
4. Impact of polymorphisms on pharmacotherapy
5. Conclusion
6. Expert opinion

informa
healthcare

Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy

Ichiro Ieiri[†], Hiroshi Takane, Takeshi Hirota, Kenji Otsubo & Shun Higuchi

[†]*Kyushu University, Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan*

There has been increasing appreciation of the role of drug transporters in pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. The clinical relevance of drug transporters depends on the localisation in human tissues (i.e., vectorial movement), the therapeutic index of the substrates and inherent interindividual variability. With regard to variability, polymorphisms of drug transporter genes have recently been reported to be associated with alterations in the pharmacokinetics and pharmacodynamics of clinically useful drugs. A growing number of preclinical and clinical studies have demonstrated that the application of genetic information may be useful in individualised pharmacotherapy for numerous diseases. However, the reported effects of variants in certain drug transporter genes have been inconsistent and, in some cases, conflicting among studies. Furthermore, the incidence of almost all known variants in transporter genes tends to be racially dependent. These observations suggest the necessity of considering interethnic variability before extrapolating pharmacokinetic data obtained in one ethnic group to another, especially in the early phase of drug development. This review focuses on the impact of genetic variations in the function of drug transporters (ABC, organic anion and cation transporters) and the implications of these variations for pharmacotherapy from pharmacokinetic and pharmacodynamic viewpoints.

Keywords: drug transporter, genetic polymorphism, pharmacodynamics, pharmacokinetics

Expert Opin. Drug Metab. Toxicol. (2006) 2(5):651-674

1. Introduction

Many types of drug transporters are expressed in various human tissues, such as the intestine, liver, kidney, skin and the brain, and play roles in drug absorption, distribution and excretion. Accordingly, it is reasonable to hypothesise that factors influencing transport capability could lead to important consequences for interindividual differences in disposition kinetics and interaction profiles of clinically useful drugs, susceptibility to side effects, and treatment efficacy. Among these factors, genetic polymorphism is highly important. The identification of allelic variations and their functional confirmations (i.e., genotype-phenotype relationship) is a necessary step towards the use of genetic information for individualised pharmacotherapy. These backgrounds have led to the study of single nucleotide polymorphisms (SNPs), which has progressed rapidly and generated remarkable findings, and some SNPs have been shown to alter both the expression and function of their gene products. This review highlights recent studies by the groups of Ieiri and others on the role of drug transporter gene polymorphisms in pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. The scope of this review is strictly limited to

Table 1. General features of drug transporters (localisation in human tissues, substrates and inhibitors)

Name (gene nomenclature)	Chromosome localisation	Main localisation (tissue or subcellular)	Substrates (clinically useful drugs)	Inhibitors (clinically useful drugs)
MDR1 or P-gp (ABCB1)	7q21.1	Canalicular membrane (hepatocytes) Brush-border membrane of proximal tubular cells (kidney) Brush-border membrane (enterocytes) Capillary endothelial cells (brain and testis) Placental trophoblast	Anticancers (docetaxel, etoposide, paclitaxel, topotecan, vinblastine) Antihypertensives (diltiazem, losartan) Antiarrhythmics (digoxin, verapamil) Antivirals (indinavir, nelfinavir) Antibiotics (erythromycin, sparfloxacin) Immunosuppressants (cyclosporin, tacrolimus) Others (cimetidine, fexofenadine, loperamide, phenytoin, morphine, ondansetron)	Amiodarone, amitriptyline, diltiazem, dipyridamole, phenothiazines, propafenone, propranolol, quinidine, spironolactone, tamoxifen
MRP2 (ABCC2)	10q24	Canalicular membrane (hepatocytes) Brush-border membrane of proximal tubular cells (kidney)	Bilirubin, diglucuronide, sulfates, glutathione conjugates, benzbromarone, indomethacin, vinblastine, telmisartan	Cyclosporin, glibenclamide
BCRP (ABCG2)	4q22	Canalicular membrane (hepatocytes) Apical membrane of syncytiotrophoblast cells (placenta, membrane facing maternal blood) Luminal membranes of villous epithelial cells (small intestine and colon)	Epirubicin, topotecan, doxorubicin, daunorubicin, etoposide, SN-38, reserpine	
OATP1A2 or OATP-A (SLCO1A2)	12p12	Cerebral endothelial cells luminal membrane (intestinal enterocytes)	Thyroid hormones (T4 and T3), prostaglandin E2, fexofenadine, quinidine	Dexamethasone, erythromycin, quinidine, verapamil
OATP1B1 or OATP-C (SLCO1B1)		Basolateral (sinusoidal) Plasma membrane (hepatocytes)	Thyroid hormones (T4 and T3), methotrexate, pravastatin, rifampicin, prostaglandin E2	
OATP1B3 or OATP8 (SLCO1B3)		Basolateral (sinusoidal) Plasma membrane (hepatocytes)	Thyroid hormones (T4 and T3), leukotriene C4, digoxin, methothrexate, rifampicin	
OATP2B1 or OATP-B (SLCO2B1)	11q13	Basolateral (sinusoidal) Plasma membrane (hepatocytes) Apical membrane (enterocytes)	Narrow substrate specificity (pH dependent?)	
OCT1 (SLC22A1)	6q26	Basolateral (sinusoidal) Plasma membrane (hepatocytes)	Acyclovir, ganciclovir, metformin	Acebutolol, amantadine, cimetidine, disopyramide, midazolam, prazosin, quinidine, verapamil
OCT2 (SLC22A2)		Basolateral membrane of proximal tubular cells (kidney) Apical side of the distal tubule (kidney)?	Amantadine, metformin, neurotransmitters, monoamine	Desipramine, procainamide
OCT3 (SLC22A3)	6q26 – 27	Placenta	Cimetidine, tyramine, neurotransmitters, monoamine	Clonidine, desipramine, imipramine, prazosin, procainamide

BCRP: Breast cancer-resistance protein; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; OCT: Organic cation transporter; MDR: Multi-drug resistance; MRP: Multi-drug resistance-associated protein; P-gp: P-glycoprotein.

Table 1. General features of drug transporters (localisation in human tissues, substrates and inhibitors) (continued)

Name (gene nomenclature)	Chromosome localisation	Main localisation (tissue or subcellular)	Substrates (clinically useful drugs)	Inhibitors (clinically useful drugs)
OAT1 (SLC22A6)	11q12.3	Basolateral membrane of proximal tubular cells (kidney)	Methotrexate	β -Lactam antibiotics, diuretics, NSAIDs, probenecid
OAT2 (SLC22A7)	6q21.1 – 2	Basolateral (sinusoidal) Plasma membrane (hepatocytes)	Methotrexate, prostaglandin E2	
OAT3 (SLC22A8)	11q12.3	Basolateral membrane of proximal tubular cells (kidney) Brush-border membrane of choroid plexus cells and in capillary endothelial cells (brain)	Cimetidine, methotrexate, salicylate, prostaglandin E2	

BCRP: Breast cancer-resistance protein; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; OCT: Organic cation transporter; MDR: Multi-drug resistance; MRP: Multi-drug resistance-associated protein; P-gp: P-glycoprotein.

observations from human (healthy volunteers and patients) studies. This review focuses on the following transporters: ABC transporters (P-glycoprotein [P-gp]/multi-drug resistance 1 [MDR1/ABCB1], multi-drug resistance-associated protein 2 [MRP2/ABCC2] and breast cancer-resistance protein [BCRP/ABCG2]), organic anion-transporting polypeptide family (OATP1A2 [OATP-A]/SLCO1A2, OATP1B1 [OATP-C]/SLCO1B1, OATP1B3 [OATP8]/SLCO1B3 and OATP2B1 [OATP-B]/SLCO2B1), organic anion transporter family (OAT1/SLC22A6, OAT2/SLC22A7 and OAT3/SLC22A8) and organic cation transporter family (OCT1/SLC22A1 and OCT2/SLC22A2).

2. General features

2.1 Localisation in human tissues and basic function

P-gp/MDR1 (ABCB1) is expressed in the small and large intestines, adrenal gland, placental trophoblasts, kidney, liver, pancreas (pancreatic ductile cell) and capillary endothelial cells of the brain and testes (Table 1) [1-4]. Evidence including findings in knockout mice support that P-gp excretes substrate drugs via the canalicular membrane of hepatocytes into the bile, via the brush-border membrane of enterocytes into the gut lumen and via the brush-border membrane of proximal tubules into the urine [5,6]. P-gp in trophoblasts and endothelial cells of the blood-brain barrier (BBB) contribute to the function of blocking the transfer of xenobiotics across the human placenta and preventing the entry of substrates into the CNS [7-9].

Although at least 13 structurally and functionally related family members have been identified in MRPs (ABCC proteins), their localisation, expression levels and substrate specificity are different [10,11]. MRP2 (ABCC2 protein) is expressed at the apical membrane in liver hepatocytes, renal proximal tubule cells and enterocytes of the intestine [12-15], and plays roles in the biliary excretion, intestinal excretion and urinary excretion of the substrates [10,11].

Similar to P-gp and MRP2, BCRP (ABCG2 protein) is expressed at the apical membrane in the placenta (trophoblast

cells), liver (bile canalicular membrane of hepatocytes), kidney and intestine (enterocytes) [16-19]. The tissue distribution of BCRP suggests that its major physiological role may be the regulation of intestinal absorption and biliary secretion of substrates, and protection of the fetus and brain from toxic xenobiotics. Unlike most other ABC transporters (e.g., P-gp and MRPs), which are characterised by 2 nucleotide-binding domains (NBD) and 12 transmembrane domains (TMD), BCRP has a single NBD at the amino terminus followed by 6 TMDs. Thus, BCRP is a so-called half-transporter and may form a homodimer, although heterodimeric forms are possible [20-24].

OATP1A2 (OATP-A) was first isolated from human liver; however, subsequent studies have identified its expression in the brain, lung, kidney and testes [25,26]. Recently, OATP1A2 has been reported to be expressed on the luminal membrane of human intestinal enterocytes, and to play a possible role in fexofenadine absorption from the intestine [26,27].

Both OATP1B1 (OATP-C) and -3 (OATP8; 80% amino acid identity to OATP-C) have liver-specific tissue distribution [28-31]. Because the uptake of substrates from the blood into hepatocytes, mediated by uptake transporters in the basolateral membrane, is the first step in the hepatocellular elimination process in the human body, the role of these transporters in the liver is of special interest. So far, the functional characterisation of OATP1B1 in the human body has been elucidated progressively among the OATP family due to its liver-specific expression.

Similar to OATP1B1 and -3, OATP2B1 (OATP-B) is predominantly found in the liver, but is also expressed in various tissues, including the brain, lung, kidney, placenta, heart, intestine and testis [32,33]. OATP2B1 is found on the basolateral membrane of hepatocytes, suggesting that this transporter functions in an uptake capacity to remove substrates from the portal circulation [33].

OAT1 and -3 are substantially expressed in the kidney, and localised on the basolateral membrane of the proximal tubules [34,35]. They uptake substrates from the blood side into the proximal tubule cell [36]. Because of key molecules in

renal excretion, OAT1 and -3 have been reported to be responsible for antibiotic- or antiviral-related nephrotoxicity [37-40]. In general, OAT family members are mainly expressed in the kidney; however, OAT2 is abundantly expressed on the basolateral membrane of the liver and, to a lesser extent, in the kidney [41,42]. In the brain, OAT3 is localised on the brush-border membrane of choroids plexus cells, suggesting it functions as the blood-cerebrospinal fluid barrier [43,44].

OCT1 is primarily expressed in the basolateral membrane of hepatocytes and is thought to play a fundamental role in the uptake of substrates into the liver [45-48]. In contrast, OCT2 is detected predominantly in the kidney and is likely to be the major transporter for the uptake of many cations from the blood sides into renal epithelial cells [48]. OCT3 has much more widespread tissue distribution at the mRNA level: aorta, skeletal muscle, prostate, salivary gland, adrenal gland and placenta [49]. Among these tissues, the placental expression level is relatively high.

2.2 Substrate drugs

P-gp accepts a broad spectrum of structurally and functionally unrelated drugs (Table 1). P-gp substrates, inducers and inhibitors are listed in detail elsewhere [50-52]. Interestingly, there is a strong overlap in substrate specificity and tissue distribution between P-gp and CYP3A4/5 [53,54].

MRP2 also has broad substrate specificity covering anti-cancer drugs [55,56] and organic anions derived from phase I and II metabolism of xenobiotics [57-59].

BCRP recognises various compounds such as negative or positive charge, organic anions and sulfate conjugates [60,61]; however, there is considerable, but not complete, overlap in substrates, especially for anticancer drugs among P-gp, MRP2 and BCRP [62,63].

In general, the substrate specificity of most OATPs is extremely broad and shows substantial overlap between different members of the superfamily. Substrates of OATP1A2 include various endogenous compounds such as bile acids, steroid hormones and thyroid hormones [25,64-66]. In contrast, information on the substrate specificity of OATP2B1 is limited at present [33]. OATP1B1 is involved in the hepatic uptake of a broad array of endogenous compounds such as leukotriene C₄, prostaglandin E₂, bilirubin and its glucuronides conjugates [29,67]. Furthermore, a variety of drugs, including 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA-reductase) inhibitors (e.g., pravastatin and pitavastatin), have been identified as OATP1B1 substrates [30,68,69]. Although OATP1B3 shares substrates with OATP1B1, OATP1B3 is the only OATP member known to transport digoxin [31,33,70].

Substrates of OAT1 and -3 include relatively small and hydrophilic organic anions, such as methotrexate, antiviral agents, β -lactam antibiotics and NSAIDs [40,71,72]. OAT2 also transports small and hydrophilic organic anions including salicylate and indometacin [73].

OCT1, -2 and -3 all transport a broad range of structurally diverse organic cations with extensively overlapping substrate

specificities [45]. Clinically useful drugs for which transport has been demonstrated include antiparkinsonians (amantadine), antidiabetics (biguanide metformin) and the H₂-receptor agonist cimetidine [45].

3. Sites of polymorphisms and allelic frequency in different ethnic populations

ABCB1, the MDR1 gene, is located on chromosome 7 at q21, with 28 exons encoding a protein of 1280 amino acids [74]. Recently, Bodor *et al.* [75] used several different human cell lines as well as lymphocytes and liver samples to investigate eventual differences between tissues and/or subjects regarding the *ABCB1* gene locus, and confirmed the length of the *ABCB1* gene is most likely 209 kb, as indicated in the database (accession number NT007933). The first evidence of the presence of naturally occurring polymorphisms in human *ABCB1* was reported by Mickley *et al.* [76] who found two SNPs in exon 21 (2677G→T) and 24 (2995G→A) (Figures 1 and 2). Subsequently, screening of the entire *ABCB1* gene has been undertaken by various laboratories and, so far, numerous SNPs have been identified [77-82]. Some SNPs are nonsynonymous; for example, G→T (2677G→T) and G→A (2677G→A) transversions at position 2677 in exon 21, located on the intracellular side of P-gp after transmembrane region 10, result in an amino acid change from Ala at codon 893 to Ser and Thr, respectively. In contrast, 1236C→T (exon 12) and 3435C→T (exon 26) are synonymous. Interestingly, some SNPs, such as 1236C→T, 2677G→T/A and 3435C→T are closely linked; thus, haplotype-oriented assignment has been taken into consideration in recent genotype-phenotype studies [78,83-86].

The allelic frequency distributions of SNPs in *ABCB1* have been reported in various racial populations (Table 2). The incidence of the most known SNPs, but also haplotypes, is highly racially dependent. The above-mentioned three variants are found at 45 – 55% frequency in Caucasians and 35 – 50% in Japanese, but only at 5 – 10% frequency in African-Americans. Interethnic differences in the distribution of the variants are a possible cause of interethnic differences in the pharmacokinetics of P-gp substrate drugs. Differences in the oral bioavailability of ciclosporin and tacrolimus and the incidence of resistance and more aggressive tumours are illustrated as samples [87-90].

ABCC2 (MRP2 gene) is composed of 32 exons encoded by an ~ 45-kb gene located on chromosome 10q24 [91,92]. Similar to the *ABCB1* gene, numerous variations have been identified in the *ABCC2* gene. Genetic analysis of *ABCC2* is well documented in patients with Dubin-Johnson syndrome (DJS), an autosomal recessive disorder characterised by conjugated hyperbilirubinaemia. At present, at least 16 variants have been identified in DJS patients, and a wide variety of genetic mechanisms, including missense mutation, nonsense mutation, splice site mutation and deletion mutation, are responsible for DJS [93]. In healthy Japanese volunteers




Figure 1. Schematic representation of secondary structures in drug transporters, with some nucleotide substitutions.

BCRP: Breast cancer-resistance protein; Exc: Extracellular; Mnb: Membrane; Inc: Intracellular; NBD: Nucleotide-binding domain; P-gp: P-glycoprotein.




Figure 2. Schematic representation of secondary structures in drug transporters, with some nucleotide substitutions.

Exc: Extracellular; Inc: Intracellular; Mnb: Membrane; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; OCT: Organic cation transporter.

Table 2. Summary of racial genetic data of naturally occurring variations of human drug transporters

Gene	Mutation	Location	Effect	Allelic frequency (n)		
				Japanese (48 – 220)	Caucasians (37 – 461)	African- Americans (23 – 200)
ABCB1 (MDR1)	-129T→C	Exon 1b	Noncoding	0.94/0.06	0.94 – 0.97/ 0.03 – 0.06	
	1236C→T	Exon 12	Synonymous	0.35/0.65	0.54 – 0.66/ 0.34 – 0.46	0.79 – 0.85/ 0.15 – 0.21
	2677G→(T/A)	Exon 21	893Ala→(Ser/Thr)	0.36 – 0.44/ 0.36 – 0.42/ 0.20 – 0.22	0.50 – 0.56/ 0.38 – 0.46/ 0.02 – 0.10	0.85 – 0.89/ 0.10 – 0.15/ 0.00 – 0.01
	3435C→T	Exon 26	Synonymous	0.51 – 0.62/ 0.38 – 0.49	0.43 – 0.54/ 0.46 – 0.57	0.74 – 0.84/ 0.16 – 0.26
ABCC2 (MRP2)	-24C→T	Promoter	Noncoding	0.81/0.19		
	1249G→A	Exon 10	417Val→Ile	0.88/0.13		
	2302C→T	Exon 18	768Arg→Trp	0.99/0.01		
	2366C→T	Exon 18	789Ser→Phe	0.99/0.01		
	4348G→A	Exon 31	1450Ala→Thr	0.99/0.01		
ABCG2 (BCRP)	34G→A	Exon 2	12Val→Met	0.81 – 0.83/ 0.17 – 0.19	0.90 – 0.96/ 0.04 – 0.10	0.94/0.06
	376C→T	Exon 4	126Gln→ (stop codon)	0.98 – 0.99/ 0.01 – 0.02	1.00/0.00	1.00/0.00
	421C→A	Exon 5	141Gln→Lys	0.67 – 0.73/ 0.27 – 0.33	0.86 – 0.89/ 0.11 – 0.14	0.95 – 0.97/ 0.02 – 0.05
	1515C (deletion)	Exon 13	509Met→ (stop codon)	0.995/0.005		
SLCO1A2 (OATP-A)	38T→C	Exon 1	13Ile→Thr		0.89 – 0.94/ 0.06 – 0.11	0.98/0.02
	382A→T	Exon 4	128Asn→Tyr		1.00/0.00	0.99/0.01
	516A→C	Exon 5	172Glu→Asp		0.95 – 0.98/ 0.02 – 0.05	0.98/0.02
	559G→A	Exon 5	187Ala→Thr		0.99/0.01	1.00/0.00
	2003C→G	Exon 14	668Thr→Ser		0.99/0.01	0.96/0.04
SLCO1B1 (OATP-C)	-11187G→A	Promoter	Noncoding		0.93/0.07	
	388A→G	Exon 4	130Asn→Asp	0.37/0.63	0.53 – 0.69/ 0.31 – 0.47	0.25/0.75
	521T→C	Exon 5	174Val→Ala	0.84 – 0.89/ 0.11 – 0.16	0.82 – 0.88/ 0.12 – 0.18	0.98/0.02
SLCO1B3 (OATP8)	334T→G	Exon 3	112Ser→Ala	0.70/0.30	0.76/0.24	0.49/0.51
	699G→A	Exon 6	233Met→Ile	0.70/0.30	0.76/0.24	0.49/0.51
SLCO2B1 (OATP-B)	9-bp deletion	Exon 2	Frame shift	0.93/0.07		
	1457C→T	Exon 10	486Ser→Phe	0.69/0.31	0.86/0.14	0.63/0.37
SLC22A6 (OAT1)	149G→A	Exon 1	50Arg→His		1.00/0.00	0.97/0.03
	311C→T	Exon 1	104Pro→Leu		1.00/0.00	0.99/0.01

BCRP: Breast cancer-resistance protein; MDR: Multi-drug resistance; MRP: Multi-drug resistance-associated protein; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; OCT: Organic cation transporter.

Table 2. Summary of racial genetic data of naturally occurring variations of human drug transporters (continued)

Gene	Mutation	Location	Effect	Allelic frequency (n)		
				Japanese (48 – 220)	Caucasians (37 – 461)	African- Americans (23 – 200)
SLC22A8 (OAT3)	677T→C	Exon 4	226Ile→Thr		0.99/0.01	1.00/0.00
	767C→T	Exon 4	256Ala→Val		1.00/0.00	0.99/0.01
	877C→T	Exon 5	293Arg→Trp		1.00/0.00	0.98/0.02
	1361G→A	Exon 8	454Arg→Gln		1.00/0.01	0.99/0.01
	1166C→T	Exon 8	389Ala→Val	0.99/0.01		
	181C→T	Exon 1	61Arg→Cys	1.00/0.00	0.91 – 0.93/ 0.07 – 0.09	1.00/0.00
	262T→C	Exon 1	88Cys→Arg	1.00/0.00	0.99/0.01	1.00/0.00
	480C→G	Exon 2	160Phe→Leu	0.89/0.11	0.78 – 0.93/ 0.07 – 0.22	0.99/0.01
	1022C→T	Exon 6	341Pro→Leu	0.84/0.16	1.00/0.00	0.92/0.08
	17857G→A	Exon 7	401Gly→Ser	1.00/0.00	0.97 – 0.99/ 0.01 – 0.03	0.99/0.01
SLC22A1 (OCT1)	17878A→G	Exon 7	408Met→Val	0.17/0.83	0.40/0.60	0.26/0.74
	17914(ATG) deletion	Exon 7	420Met deletion	1.00/0.00	0.81 – 0.84/ 0.16 – 0.19	0.97/0.03
	32870G→A	Exon 9	465Gly→Arg	1.00/0.00	0.96 – 0.99/ 0.01 – 0.04	1.00/0.00
	495G→A	Exon 2	165Met→Ile	1.00/0.00	1.00/0.00	0.99/0.01
	601C→T	Exon 3	200Thr→Met	0.99/0.01	1.00/0.00	1.00/0.00
	808G→T	Exon 4	270Ala→Ser	0.83 – 0.87/ 0.13 – 0.17	0.84/0.16	0.89/0.11
SLC22A2 (OCT2)	1198C→T	Exon 7	400Arg→Cys	1.00/0.00	1.00/0.00	0.98/0.02
	1294A→C	Exon 8	432Lys→Gln	1.00/0.00	1.00/0.00	0.99/0.01
SLC22A3 (OCT3)	1270A→T	Exon 7	424Thr→Ser	0.99/0.01		

BCRP: Breast cancer-resistance protein; MDR: Multi-drug resistance; MRP: Multi-drug resistance-associated protein; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; OCT: Organic cation transporter.

(n = 48), Ito *et al.* [79] analysed the entire *ABCC2* gene and found six SNPs. Among them, 1249G→A in exon 10, a non-synonymous mutation (417Val→Ile) was frequently observed with an allelic frequency of 12.5%. Only one heterozygote (allelic frequency is 1%) was observed out of 48 volunteers for 2302C→T (768Arg→Trp in exon 18), 2366C→T (789Ser→Phe in exon 18) and 4348G→A (1450Ala→Thr in exon 31).

The *ABCG2* gene is located at 4q22 and encodes a 72-kDa membrane protein composed of 655 amino acids [22,94]. So far, systematic mutation analysis of the *ABCG2* gene has been performed in various ethnic populations, and > 40 SNPs have been identified [95–98]. The two most frequent non-synonymous mutations identified in humans are 34G→A (12Val→Met in exon 2) and 421C→A (141Gln→Lys in exon 5). When comparing the frequencies of the three major variants (i.e., 34G→A, 376C→T and 421C→A) among three

ethnic populations (Japanese, Caucasian and African-American), Japanese subjects had significantly higher frequencies of 34G→A and 421C→A than the other two ethnic groups. Interestingly, these three variants occurred simultaneously, and the following four haplotypes were identified: G-C-C, G-C-A, A-C-C and G-T-C with their corresponding allelic frequencies of 46, 35, 18 and 1%, respectively [97]. Thus, similar to other transporter genes, the genetic frequency of *ABCG2* appears to be dependent on ethnicity.

Two recent studies have been conducted to identify SNPs in the *SLCO1A2* gene using genomic DNA samples from various ethnic populations [99,100]. Iida *et al.* [99] screened 27-kb wide for *SLCO1A2* in a Japanese population (n = 48). They did not detect SNPs in the exonic regions, but identified several variations in the 5'-flanking region. Among them, three variations (-916G→A, -526T→C and -189A/ins) are of interest because they are located within important transcriptional regulatory

regions (e.g., hepatic nuclear factor 1 α). In contrast, Lee *et al.* [100] screened all 14 exons of *SLCO1A2* and identified 6 nonsynonymous SNPs with an allelic frequency in the range of 1.0 – 11.1%. They also demonstrated that allelic frequencies of six identified SNPs are dependent on ethnicity using ethnically defined DNA (European, African, Chinese and Hispanic-Americans).

So far, at least 15 nonsynonymous *SLCO1B1* SNPs have been identified in various ethnic populations. Among them, two commonly occurring nonsynonymous SNPs, 388A→G (130Asn→Asp in exon 4) and 521T→C (174Val→Ala in exon 5), are of special interest, due to not only their marked consequences in transport capability, but also interethnicity in allelic frequency. In addition to SNP-based analysis, haplotype-oriented assessment has also been well documented [101–104]. At least 17 haplotypes have been recognised so far. Major haplotypes in humans are as follows: *SLCO1B1**1a (130Asn174Val), -*1b (130Asp174Val), -*5 (130Asn174Ala), -*15 (130Asp174Ala) and -*17 (-11187G→A130Asp174Ala). Although the frequency of *SLCO1B1**5 is extremely low in Asian and black populations, the frequency in Caucasians is ~ 15%. In contrast, *SLCO1B1**15 is more common in Asian populations [69,101,103]. Interestingly, although the allelic frequency of 521T→C is similar between Asians and Caucasians (~ 15%), their haplotype patterns are different. In Asian populations, the 521T→C polymorphism is combined with the 388A→G variant. In recent Japanese data, the -11187G→A variant is also tightly linked (~ 100%) to the *SLCO1B1**15 allele [105].

A recent report has described the identification of SNPs in *SLCO1B3* in a population of Japanese individuals [99]. Based on this study and the authors' unpublished data, at least two nonsynonymous SNPs, 334T→G (112Ser→Ala in exon 3) and 699G→A (233Met→Ile in exon 6), exist with an allelic frequency ranging 0.24 – 0.51. Because the frequencies of these two SNPs were identical in all ethnic populations studied, these SNPs may occur simultaneously (being haplotyped).

Interestingly, collective evidence indicates that the frequency of nonsynonymous SNPs in OAT family genes (*SLC22A6*, *SLC22A7* and *SLC22A8*) appears extremely lower (< 1%) [99,103,106,107], suggesting these genes are relatively intolerant of nonsynonymous changes. Fujita *et al.* [106] focused on *SLC22A6* (OAT1 gene) and identified 6 nonsynonymous SNPs using 267 DNA samples from an ethnically diverse population. Only two SNPs, 149G→A (50Arg→His in exon 1) and 877C→T (293Arg→Trp in exon 5), were present at ≥ 1% in at least one ethnic population. They also identified 17 distinct haplotypes. Xu *et al.* [107] resequenced the coding regions of four OAT member genes from an ethnically diverse, healthy population (n = 192), and identified two nonsynonymous SNPs in *SLC22A6*, three in *SLC22A7*, one in *SLC22A8* and eight in *SLC22A9*, with an allelic frequency in the range of 0.01 – 0.03.

Some groups have screened for genetic variants of *SLC22A1* (encoding OCT1) in various ethnic populations [108–110].

Kerb *et al.* [110] identified 4 nonsynonymous SNPs (61Arg→Cys, 88Cys→Arg, 160Phe→Leu, 401Gly→Ser) and 1 deletion (420Met→del) in 57 Caucasian samples, with respective allelic frequencies of 9.1, 0.6, 22.0, 3.2 and 16.0%. Subsequently, Shu *et al.* [109] also detected numerous variations from five different ethnic groups. Some known SNPs (e.g., 41Phe→Leu and 117Pro→Leu) were observed in at least one ethnic population, suggesting ethnic diversity in *SLC22A1* polymorphism.

Similar to *SLC22A1*, several genetic variants in the coding region of *SLC22A2* (OCT2 gene) have been identified [111,112]. *SLC22A2* polymorphism was recently investigated comprehensively by screening all 11 exons as well as intronic sequence using 247 ethnically diverse DNA samples [112]. Among eight nonsynonymous SNPs, four (165Met→Ile, 270Ala→Ser, 400Arg→Cys and 432Lys→Gln) were polymorphic, with ethnic-specific allelic frequencies ≥ 1%. Novel variations, including SNPs and deletion, have also been reported in recent Japanese studies [111,113].

4. Impact of polymorphisms on pharmacotherapy

4.1 Pharmacokinetic consequences

In the pharmacogenomics of the *ABCB1* gene, Hoffmeyer *et al.* [77] first reported that a synonymous SNP, 3435C→T, was associated with significantly reduced intestinal P-gp content in subjects with the T/T genotype in comparison with subjects homozygous for the C allele (C/C), leading to higher steady-state plasma concentrations after the oral administration of digoxin in T/T subjects. After this report, a remarkably large number of clinical studies have been conducted around the world on the association of the *ABCB1* genotype and pharmacokinetic phenotypes. Most studies have focused on SNPs in the following two exons, 21 (2677G→T/A) and 26 (3435C→T); however, as summarised in recent reviews [50,82,114–116] and Table 3, the published observations conflict even when using the same probe drug and even among the same racial group. For example, Sakaeda *et al.* [117] conducted an *ABCB1* genotype–phenotype study using digoxin as a probe and found that the AUC of digoxin in the absorption phase was significantly lower in subjects with 3435T/T genotype than in 3435C/C subjects. These observations are in line with a finding by Kim *et al.* [81], but are in contrast to the findings of Hoffmeyer *et al.* [77] and Kurata *et al.* [118]. In order to overcome these disagreements, some researchers have incorporated haplotype-oriented analysis into the genotype–phenotype study [83–86,119]. Recent studies have demonstrated that haplotype assessment represents more precise prediction of the pharmacokinetics of certain drugs such as digoxin [119] and ciclosporin [83].

Wang *et al.* [120] introduced new approach for the evaluation of the 3435C→T variant. The level of mRNA expression can be regulated in a *cis* or *trans* fashion, and the *cis*-acting polymorphism changes the expression of the gene transcript

Table 3. Impact of *ABCB1* gene variants on PK of drug substrates

Polymorphism	Population	Drug	Functional effect of the variant allele	Ref.
3435C→T	Caucasian HV	Digoxin	Increased AUC after single dose for T/T	[77]
	Caucasian HV	Digoxin	Higher AUC and C_{max} under steady state for T/T*	[119]
	Japanese HV	Digoxin	Higher BA after single dose for T/T*	[118]
	Caucasian and African HV	Digoxin	Higher AUC after single dose for T/T	[191]
	Caucasian HV	Digoxin	No difference in PK data after single dose	[192]
	Japanese HV	Digoxin	Decreased AUC after single dose for T/T	[117]
	Korean HV	Fexofenadine	Higher AUC and C_{max} after single dose for T/T*	[193]
	Caucasian HV	Fexofenadine	No difference in PK data after single dose	[194]
	Caucasian and African HV	Fexofenadine	Decreased AUC after single dose for T/T	[81]
	Asian HT patients	Ciclosporin	Higher AUC under steady state for T/T*	[84]
	Caucasian RT patients	Ciclosporin	No difference in C_{min} under steady state	[195]
	Caucasian and African HV	Ciclosporin	No difference in AUC after single dose	[196]
	Caucasian RT patients	Ciclosporin	Decreased AUC under steady state for C/T and T/T	[197]
	LT patients	Ciclosporin	Higher plasma (or serum) level/dose ratio under steady state for T/T	[198]
	RT patients	Tacrolimus	Higher C_{min} under steady state for T/T	[199]
	HT paediatric patients	Tacrolimus	Higher C_{min} under steady state for C/T and T/T	[200]
	RT patients	Tacrolimus	No difference in C_{min} under steady state	[201]
	Caucasian HV	Talinolol	No difference in AUC*	[202]
	Chinese HV	Talinolol	No difference in AUC after single dose*	[203]
	Caucasian HIV-1 patients	Nelfinavir, efavirenz	Lower C_{min} under steady state for T/T	[143]
	HIV patients	Atazanavir	Lower drug level under steady state for T/T	[204]
	Caucasian HV	Loperamide	No difference in PK data after single dose	[205]
	HV	Dicloxacillin	No difference in C_{max} after single dose	[206]
	Turkish HV	Phenytoin	Higher drug level under steady state for T/T	[207]
	Japanese schizophrenic patients	Risperidone	No difference in C_{min} under steady state	[208]
	ALL paediatric patients	Vincristine	No difference in PK data*	[160]
2677G→(T/A)	Japanese HV	Digoxin	Higher BA after single dose for T/T*	[118]
	Caucasian and African HV	Digoxin	Higher AUC after single dose for T/T	[191]
	Caucasian HV	Digoxin	No difference in PK data after single dose	[192]
	Japanese HV	Digoxin	Lower AUC after single dose for T/T	[209]
	Caucasian and African HV	Fexofenadine	Decreased AUC after single dose for T/T	[81]
	Korean HV	Fexofenadine	Decreased AUC after single dose for A/A*	[193]
	Asian HT patients	Ciclosporin	Higher AUC under steady state for T/T*	[84]
	HT paediatric patients	Tacrolimus	Higher C_{min} under steady state for G/T and T/T	[200]

*Including haplotype assessments.

ALL: Acute lymphoblastic leukaemia; BA: Bioavailability; HT: Heart transplant; HV: Healthy volunteers; LT: Liver transplant; PK: Pharmacokinetics; RT: Renal transplant.

Table 3. Impact of *ABCB1* gene variants on PK of drug substrates (continued)

Polymorphism	Population	Drug	Functional effect of the variant allele	Ref.
	RT patients	Tacrolimus	Higher drug level under steady state for T/T*	[210]
	Caucasian HV	Talinolol	Slightly higher in AUC for T/A and T/T*	[202]
	Chinese HV	Talinolol	No difference in AUC after single dose*	[203]
	ALL paediatric patients	Vincristine	No difference in PK data*	[160]

*Including haplotype assessments.

ALL: Acute lymphoblastic leukaemia; BA: Bioavailability; HT: Heart transplant; HV: Healthy volunteers; LT: Liver transplant; PK: Pharmacokinetics; RT: Renal transplant.

from the allele carrying the polymorphism, leading to the allelic expression imbalance. In order to test for the presence of *cis*-acting polymorphisms in human *ABCB1* that might be responsible for altered mRNA expression of the 3435T allele, they measured differences in allelic mRNA expression between the 3435T and 3435C allele using liver samples from heterozygous individuals carrying the 3435C→T SNP. They indicated that mRNA expression of the 3435C allele was significantly higher than that of the 3435T allele (3435C/3435T ratios in the range of 1.06 – 1.16). Based on the experiments including *in vitro* transfection of mixtures of *ABCB1* variants carrying all possible combinations of 1236C→T, 2677G→T and 3435C→T, they concluded that 3435C→T is the main functional polymorphism affecting mRNA levels, by altering mRNA stability. Interestingly, allelic expression imbalance has been observed in other pharmacokinetic genes such as *ABCG2*, *CYP3A5* and *CYP3A4* [97,121,122].

The question arises as to why the contribution of SNPs to the pharmacokinetics of some probes (e.g., digoxin and fexofenadine) differs among reports. The reasons for this discrepancy remain to be addressed; however, multiple tissue expression of P-gp with various vectorial movements and no suitable specific probe drug for P-gp function may contribute. Recently, Brunner *et al.* [123] measured the brain distribution of a model P-gp substrate, the calcium-channel inhibitor verapamil [124], using positron emission tomography in two groups of healthy volunteers. To these authors' knowledge, this is the first evaluation of P-gp function, as a 'gatekeeper' (i.e., regulating drug uptake to highly sensitive tissue brain), in the BBB directly. They indicate no difference in the brain distribution of [¹¹C]verapamil between the TTT haplotype (1236T, 2677T and 3435T) and the wild-type CGC haplotype (1236C, 2677G and 3435C). Because positron emission tomography has sensitivity in the lower picomolar range for tissue concentrations of drug molecules to be measured, and because P-gp-triggered active efflux may be an unyielding barrier in the brain penetration of substrate drugs, their findings that failed to show an effect of *ABCB1* gene polymorphisms on P-gp functions in the BBB are notable.

Sparreboom *et al.* [125] first studied the effects of naturally occurring, common variant *ABCG2* 421C→A on the pharmacokinetics of diflomotecan, a synthetic derivative of camptothecin, in 22 adult white patients with cancer. They

found that plasma levels of diflomotecan after intravenous administration were significantly higher (~300%) in patients with 421C/A genotype than in 421C/C patients. However, despite expectations of significant genotype-dependent regulation in intestinal absorption due to its enriched localisation, the pharmacokinetics of diflomotecan did not differ between the two genotype groups after oral administration. Although further investigation is required to resolve this issue, these observations partially agree with some *in vitro* studies, indicating that the *ABCG2* 421C→A allele is associated with low BCRP expression levels [97,126,127]. These *in vitro* observations suggest that carriers of the 421C→A allele may have decreased clearance (increased plasma levels) and/or increased bioavailability. In a preliminary fashion, Sparreboom *et al.* [128] also reported that the heterozygous 421C/A allele observed in 2 patients was associated with a 1.34-fold increased oral bioavailability of topotecan compared with that in 10 patients with the 421C/C genotype. In contrast, de Jong *et al.* [129] reported no difference in the pharmacokinetic parameters of irinotecan and SN-38 between patients with and without the *ABCG2* 421C→A allele. They noted that other processes involved in irinotecan metabolism and elimination that exhibit great interindividual variation might be overshadowing any effect of this *ABCG2* polymorphism.

As described previously, because MRP2 (ABCC2 protein) is responsible for the export of conjugated drug metabolites from hepatocytes to bile, and because many *ABCC2* variants are known to be associated with DJS, naturally occurring *ABCC2* variants are expected to be involved in large interindividual differences in pharmacokinetic and pharmacodynamic consequences of substrate drugs; however, no sufficient human data have been reported so far. To the authors' knowledge, at least two studies have been carried out to assess possible associations of genetic variants in *ABCC2* with phenotypes (i.e., cellular exposure of nelfinavir [130] and pharmacokinetics of pravastatin [102]). However, there were no significant associations between phenotype indices and SNPs and/or haplotypes at *ABCC2*.

Facilitative hepatic uptake from the portal circulation by OATP1B1 is thought to contribute to tissue selectivity and therapeutic response to HMG-CoA reductase inhibitors (statins). Nishizato *et al.* [103] screened genetic polymorphism in the *SLCO1B1* using DNA from 120 Japanese healthy

volunteers and conducted a clinical study to examine whether variants alter transport activity with pravastatin as a selective probe drug. Subjects with the *SLCO1B1**15 allele (130Asp174Ala) had reduced total and nonrenal clearance, as compared with those with the *SLCO1B1**1b allele (130Asp174Val), and the difference between *1b/*1b and *1b/*15 subjects was significant. In their study, only one subject harboured the *15/*15 genotype, with nonrenal clearance about a tenth of that in the *1b/*1b genotype. They first demonstrated that commonly occurring SNPs in the *SLCO1B1* gene are likely to be associated with altered pharmacokinetics of substrate drugs in humans. Niemi *et al.* [102] also evaluated the relationship between *SLCO1B1* variants and the pharmacokinetics of pravastatin. In heterozygous carriers of *15B (130Asp174Ala), the mean pravastatin AUC₀₋₁₂ was 93% higher compared with noncarriers and, in heterozygous carriers of *17 (-11187G→A and 130Asp174Ala), it was 130% higher compared with noncarriers. They also reported no significant associations between *SLCO2B1*, *ABCC2* or *ABCB1* polymorphisms and the pharmacokinetics of pravastatin. Based on the healthy volunteers study, Mwinyi *et al.* [104] found that *5 allele (130Asn174Ala) delayed the hepatocellular uptake of pravastatin, whereas *1b allele seemed to accelerate OATP1B1-dependent uptake of the drug. Chung *et al.* [69] characterised the effects of *SLCO1B1* alleles, *1a, *1b and *15 on the pharmacokinetics of pravastatin. Despite small sample size, the dose-normalised AUC and C_{max} of pravastatin were 1.4- and 1.8-fold higher, respectively, in subjects heterozygous for the *15 allele versus subjects not varying this allele. Similar to pravastatin, the *15 allele is suggested to be associated with decreased pravastatin uptake from blood into hepatocytes. Systematic exposure to rosuvastatin had been observed to be ~ 2-fold higher in Japanese subjects living in Japan compared with white subjects in Western Europe or the US [131-133]. Because OATP1B1 contributes to the hepatic uptake of rosuvastatin [134], in order to determine whether polymorphisms in the *SLCO1B1* gene contribute to any pharmacokinetic differences, Lee *et al.* [135] conducted a pharmacokinetic study including four racial populations. They found that *SLCO1B1* 521T→C did not account for the clear population differences in rosuvastatin exposure among white subjects and Asian groups. Although no 521C/C homozygote in Asian subjects seems to be the most likely reason for failed to show up the differences, they concluded that the pharmacogenetics of other rosuvastatin disposition pathways may better explain the ethnic differences in pharmacokinetics [136].

The H₁-receptor antagonist fexofenadine is a P-gp substrate [65]; however, association between the pharmacokinetics of fexofenadine and polymorphism of the *SLCO1B1* gene has recently been reported [137]. The mean total AUC of fexofenadine in the -11187G/G521C/C subjects was 76% higher in subjects with the 521T/C genotype and 127% higher in subjects with the 521T/T genotype. These results suggest that OATP1B1 is involved in fexofenadine exposure, and may

partly explain the conflicting observations between fexofenadine pharmacokinetics and *ABCB1* polymorphism.

Niemi *et al.* [138] investigated possible associations between the pharmacokinetics of repaglinide, a meglitinide analogue antidiabetic drug, and SNPs in genes encoding for OATP1B1, P-gp, CYP2C8 and CYP3A5 in 56 healthy subjects. Multiple regression analysis indicated that the *SLCO1B1* 521T→C and *CYP2C8**3 allele were independent predictors of the AUC_{0-∞} and C_{max} of repaglinide; the AUC_{0-∞} in the subjects with 521C/C genotype was 107 and 188% higher, respectively, than in subjects with the 521C/T or 521T/T genotype; however, surprisingly, only *SLCO1B1* -11187G→A was significantly associated with an enhanced effect of repaglinide on blood glucose, even though SNPs at positions -11187 and 521 are haplotyped.

Very recently, the authors studied the effects of polymorphism of *SLCO1B1*, particularly the *1b allele, on the pharmacokinetics of three anionic drugs, pravastatin, valsartan and temocapril in a three-way crossover manner in 23 healthy Japanese volunteers [139]. The authors found that AUC of pravastatin in *1b/*1b carriers was 65% of that in *1a/*1a carriers, and AUC of valsartan and temocapril in each subject was significantly correlated with that of pravastatin. These results suggest that: i) *SLCO1B1**1b allele enhances the hepatic uptake activity of pravastatin; and ii) OATP1B1 is one of the determinant factors governing interindividual variability in the pharmacokinetics of these three drugs. Reduction of pravastatin AUC in the *1b subjects was well consistent with the above-mentioned study conducted by Mwinyi *et al.* [104].

Two studies have examined the effects of *SLCO1B1**5 and *15 on the functional properties of OATP1B1 using cDNA transfected cells. Kameyama *et al.* [140] evaluated transport capability by transient expression system of HEK293 and HeLa cells using endogenous conjugates, estradiol-17β-D-glucuronide and estrone-3-sulfate, and statins as substrates. Kinetic analysis of pravastatin and atorvastatin showed that K_m values were not altered, but V_{max} values decreased significantly in cells expressing the variants. Immunocytochemical study showed that the variant-typed proteins were localised not only at the plasma membrane, but also in the intracellular space. In contrast, Iwai *et al.* [141] indicated that all SNP variants expressed in HEK293 cells were predominantly located on the cell surface without changes in K_m values for the transport of 17β-estradiol 17β-D-glucuronide. However, the normalised V_{max} value (by the protein expression level estimated from western blotting) for *SLCO1B1**15 was drastically decreased to < 30% compared with *1a. Although the observation of lower V_{max} values in the *SLCO1B1**15 cells was similar between the studies, the expression manner was clearly controversial. There is no good reason for this discrepancy; however, we need to be careful in expecting *in vivo* cellular localisation from the results of *in vitro* expression system.

Although many SNPs have been identified in the OCT2 gene, no pharmacogenomic human study has yet been

Table 4. Impact of the *ABCB1* (MDR1) genetic variant on PD of drug substrates and their consequences on disease states

Population (disease)	Polymorphism	Drug	Outcome marker	Effect	Ref.
Caucasian RT patients	3435C→T	Ciclosporin	Acute rejection	No significant difference	[195]
Caucasian patients (depression)	3435C→T	Nortriptyline	Nortriptyline-induced postural hypotension	Higher in T/T	[211]
Caucasian patients (HIV infection)	3435C→T	Nelfinavir, efavirenz	CD4 recovery with treatment	Higher in T/T	[143]
HIV patients	3435C→T		Virological suppression	Higher in T/T	[212]
Caucasian patients (HIV infection)	3435C→T		CD4 recovery with treatment	No significant difference	[145]
HIV patients	3435C→T	Efavirenz	Drug-induced HDL-cholesterol level	Higher in C/C	[213]
Paediatric HT patients	3435C→T 2677G→T	Corticosteroids	Steroid weaning 1 year after HT	Higher in T/T	[214]
AML patients	1236C→T 2677G→(T/A) 3435C→T	Menu of SHG-AML-96	OS and PR	Higher OS and low PR in T/T	[155]
AML patients	2677G→T		OS and PR	No significant difference	[156]
ALL patients	3435C→T		OS	No significant difference	[157]
Colon cancer patients	3435C→T		Susceptibility to colon cancer	Higher in T/T	[179]
Japanese LT patients	2677G→(T/A)	Tacrolimus	Tacrolimus-induced neurotoxicity	Higher in T/T	[161]
RT patients	3435C→T	Ciclosporin	Ciclosporin-induced tremor	No significant difference	[215]
RT patients	2677G→(T/A) 3435C→T	Ciclosporin	Ciclosporin-induced nephrotoxicity	Higher in T/T (donor side)	[162]
Lung transplant patients	2677G→T 3435C→T	Tacrolimus + prednisolone + azathiopurine	Acute persistent rejection	Higher in patients with the C allele	[216]
RT patients	3435C→T	Ciclosporin	Gingival overgrowth	No significant difference	[163]
Caucasian patients (renal epithelial cell cancer)	3435C→T		Susceptibility to renal tumour	Higher in T/T	[181]
Caucasian patients (ulcerative colitis)	3435C→T		Susceptibility to ulcerative colitis	Higher in T/T	[168]
Caucasian patients (Crohn's disease)	3435C→T		Susceptibility to Crohn's disease	No significant difference	[168]
White Spanish patients	2677G→(T/A) 3435C→T		Susceptibility to Crohn's disease	Higher in 2677T/3435C	[175]
White Scottish patients	2677G→T 3435C→T		Susceptibility to ulcerative colitis	Higher in 3435T/T	[174]
Caucasian patients (Parkinson's disease)	3435C→T		Susceptibility to Parkinson's disease	Early onset in T/T (trend)	[164]

5-HT: 5-Hydroxytryptamine; ALL: Acute lymphoblastic leukaemia; AML: Acute myeloid leukaemia; HDL: High-density lipoprotein; HT: Heart transplant; LT: Liver transplant; OS: Overall survival; PD: Pharmacodynamics; PR: Probability of relapse; RT: Renal transplant.

Table 4. Impact of the *ABCB1* (MDR1) genetic variant on PD of drug substrates and their consequences on disease states (continued)

Population (disease)	Polymorphism	Drug	Outcome marker	Effect	Ref.
Parkinson's disease patients	3435C→T		Susceptibility to pesticide-induced Parkinson's disease	Higher in C/T	[165]
Breast cancer patients	3435C→T		Response to preoperative chemotherapy	Decreased resistance in T/T	[217]
Epileptic patients	3435C→T		Response to antiepileptics	Higher in T/T	[152]
Epileptic patients	3435C→T		Response to antiepileptics	No significant difference	[154]
Cancer patients	3435C→T	5-HT ₃ receptor antagonists	Antiemetic response (granisetron)	Higher in T/T (first 24 h)	[218]
Japanese patients (schizophrenia)	2677G→(T/A) 3435C→T	Bromperidol	Response to bromperidol		[219]

5-HT: 5-Hydroxytryptamine; ALL: Acute lymphoblastic leukaemia; AML: Acute myeloid leukaemia; HDL: High-density lipoprotein; HT: Heart transplant; LT: Liver transplant; OS: Overall survival; PD: Pharmacodynamics; PR: Probability of relapse; RT: Renal transplant.

reported. A recent study of monozygotic twin pairs showed that genetic factors contribute substantially to the renal clearance of metformin [142]. Genetic variation in the OCT2 is expected to explain the large interindividual variability in the pharmacokinetics of metformin.

Fujita *et al.* [106] conducted a small family based clinical study to determine the renal elimination of a model OAT1 substrate, adefovir, with regard to a nonfunctional variant, OAT1 1361G→A. They did not observe significant differences in renal clearance or renal secretory clearance in family members heterozygous for 1361G→A allele, in comparison with family members who did not carry this variant.

In OAT3 pharmacogenomics, one study reported no remarkable differences in both the mean renal and renal secretory clearances of pravastatin among the genotypic groups evaluated (reference, 723T→A and 1166C→T) [103].

4.2 Pharmacodynamic consequences

An association of *ABCB1* gene polymorphisms with pharmacodynamic consequences was reported for HIV therapy, antiepileptic pharmacotherapy, chemotherapy, adverse effects of P-gp substrates such as immunosuppressants and tricyclic antidepressants, and others (Table 4).

Fellay *et al.* [143] have studied the association between the response to antiretroviral treatment and the *ABCB1* genotype in 123 HIV-1-infected patients treated with efavirenz or nelfinavir. They found that patients with 3435T allele have a better response to the drugs after treatment for 6 months, as determined by an increased CD4⁺ count. Haas *et al.* [144] also found that the 3435T/T genotype was associated with a decreased likelihood of virological failure and decreased emergence of efavirenz-resistant virus, but not with plasma efavirenz exposure after long-term follow up lasting up to 3 years. In contrast, Nasi *et al.* [145] and Winzer *et al.* [146] failed to find an

association between the *ABCB1* genotype and virological and immunological responses to antiretroviral therapy.

P-gp can transport antiepileptic drugs [147], and the association of the multiple-drug resistance phenotype in epilepsy with increased lesional P-gp expression levels in resected brain tissues has been speculated [148-151]. Based on these backgrounds, Siddiqui *et al.* [152] genotyped 3435C→T in 315 patients with epilepsy, and demonstrated that patients with drug-resistant epilepsy were more likely to have the C/C genotype than T/T, when compared with patients with drug-responsive epilepsy. However, similar to antiretroviral therapy, controversial observations have been reported by at least two independent laboratories [153,154].

Multi-drug resistance is one of the most serious problems in the failure of chemotherapy, and some clinical studies with regard to *ABCB1* polymorphism and clinical outcomes have been conducted; however, as shown in Table 4, contribution of the *ABCB1* gene variants on outcome markers (e.g., overall survival and probability of relapse) in acute lymphoblastic leukaemia or acute myeloid leukaemia patients is controversial among the studies [155-160].

Numerous adverse reactions including neurotoxicity, nephrotoxicity and gingival hyperplasia are sometimes observed in patients treated with immunosuppressants. Yamauchi *et al.* [161] studied the correlation of the *ABCB1* polymorphism with tacrolimus-induced neurotoxicity (e.g., convulsion and tremor) in patients after living-related donor liver transplantation, and found that the 2677T allele might be a positive predictor of toxicity. Similarly, although daily dose, trough levels, and the concentration per dose ratio were not different between case and control groups, the donor's *ABCB1* 3435T/T genotype was reported to be a predictor of ciclosporin-induced nephrotoxicity [162]. Drug transporters in salivary glands have not yet been characterised; however,

Table 5. Impact of gene variants of the drug transporters PK and PD of substrates and their effect on disease states.

Gene	Polymorphism	Population	Drug/substrate	PK	PD	Functional effect of the variant allele	Ref.
ABCG2 (BCRP)	421C→T (141Gly→Lys)	White cancer patients (n = 22)	Diflomotecan	Yes		Higher AUC for C/T	[125]
	421C→T (141Gly→Lys)	European Caucasian cancer patients (n = 84)	Irinotecan (SN-38 and SN-38G)	Yes		No significant change in PK	[129]
	421C→T (141Gly→Lys)	2 cancer patients	Topotecan	Yes		Higher BA for C/T	[128]
SLCO1B1 (OATP1B1)	*15	Japanese HV	Pravastatin	Yes		Higher AUC for *15/*15	[103]
	521T→C	Japanese hyperlipidaemia (n = 66)	HMG-CoA reductase inhibitors		Response to cholesterol-lowering effect	Lower in C/T	[188]
	*15	Japanese patients	Pravastatin, atorvastatin		Susceptibility to statin-induced myopathy	Higher in *15 patients	[220]
	521 T→C -11187G→A	Caucasian HV (n = 20)	Fexofenadine	Yes		Higher AUC in C/C	[137]
	*17	Caucasian HV (n = 41)	Pravastatin	Yes	Response to cholesterol synthesis inhibition	Higher AUC and smaller response in *17 subjects	[189]
	521 T→C -11187G→A	HV (n = 56)	Repaglinide	Yes	Response to glucose-lowering effect	Higher AUC in C/C Increased response in G/A	[138]
	388A→G 521T→C	4 racial populations (HV)	Rosuvastatin	Yes		Higher AUC for C/T and C/C	[135]
	*1a, *1b, *15	Korean HV (n = 24)	Pitavastatin	Yes		Higher AUC for *15 subjects	[69]
	*1a, *1b, *5	Caucasian HV (n = 30)	Pravastatin	Yes		Higher AUC for *5 subjects Lower AUC for *1b subjects	[104]
	*15B, *17	Caucasian HV (n = 41)	Pravastatin	Yes		Higher AUC for *15B and *17 subjects	[102]
SLC22A6 (OAT1)	1361G→A (454Arg→Gln)	1 African-American family	Adefovir	Yes		No change in renal clearance	[106]
SLC22A8 (OAT3)	1166C→T (389Ala→Val)	1 heterozygote (Japanese HV)	Pravastatin	Yes		No change in renal clearance	[103]

BA: Bioavailability; BCRP: Breast cancer-resistance protein; HMG-CoA: 3-Hydroxy-3-methylglutaryl coenzyme A; HV: Healthy volunteers; OAT: Organic anion transporter; OATP: Organic anion-transporting polypeptide; PD: Pharmacodynamics; PK: Pharmacokinetics.

Drozdziak *et al.* [163] reported no association between *ABCB1* polymorphism and gingival overgrowth in kidney transplant patients with ciclosporin treatment.

Although the physiological role of P-gp is not fully elucidated, it is conceivable that P-gp acts as a cellular barrier at numerous levels in the human body. Therefore, genotype-dependent P-gp function may contribute to disease

susceptibility. So far, a number of studies have been reported on the association of *ABCB1* polymorphism with the following diseases: Parkinson's disease [164-167], inflammatory bowel diseases (ulcerative colitis and Crohn's disease) [168-175], cancers (leukaemia [155,176,177], colon cancers [178-180], renal epithelial tumours [181] and glioma [182]), primary biliary cirrhosis [183], rheumatoid arthritis [184] and hypertension [185].

Previous human studies agree that among numerous SNPs in the *SLCO1B1* gene, 521T→C (174Val→Ala) plays an important role in the transport capability, reducing hepatic uptake of pravastatin (Table 5) [103,104]. Because the target tissue of pravastatin is hepatocytes [186,187], subjects with this allele may exhibit reduced cholesterol-lowering effect of pravastatin due to lower pravastatin concentration in the hepatocytes, despite high plasma levels and AUC of pravastatin. At least two studies have been conducted to clarify this hypothesis. Tachibana-Iimori *et al.* [188] conducted a retrospective study on 66 patients who underwent treatment for hyperlipidaemia with HMG-CoA reductase inhibitors. They found that patients with the 521C allele showed an attenuated total-cholesterol-lowering effect compared with those homozygous for the 521T allele. Niemi *et al.* [189] investigated the association between polymorphism in the *SLCO1B1* and plasma concentrations of lathosterol and cholesterol up to 12 h after the intake of a single dose of pravastatin 40 mg in 41 healthy Caucasian subjects, and found that the plasma lathosterol level and lathosterol to cholesterol level ratio, markers of the rate of cholesterol synthesis *in vivo*, were significantly lower among the three heterozygous carriers of the *SLCO1B1**17 haplotype as compared with noncarriers. Both studies suggest that the 521T→C polymorphism modulates the lipid-lowering efficacy of HMG-CoA reductase inhibitors.

5. Conclusion

The polymorphism of genes encoding drug transporters is a useful marker to interpret large interindividual differences in the pharmacokinetics and response (pharmacodynamics) of clinically important drugs, and a great deal of effort is now being directed at assessing genotype–phenotype relationships not only in the clinical setting, but also at all stages of drug development. Numerous drug transporters, except the transporters described here, may also play an important role in the human body. Gene-knockout animals and expression cell systems are now available for the characterisation of basic traits such as substrate specificity, localisation and vectorial movement. Thus, in order to elucidate their *in vivo* functions more precisely, it seems appropriate to integrate the results from *in vitro* experiments/animal studies into the human study. Further refining of this integration will provide more precise and useful observations, allowing for truly genome-based scientific pharmacotherapy.

6. Expert opinion

Genetic polymorphisms have been identified in most known drug transporters. Some of these variants were shown to have an impact on pharmacokinetic and pharmacodynamic consequences in pharmacotherapy, but unfortunately, functional confirmation remains to be elucidated for most of these variants. We are now beginning to elucidate and understand the consequences of these variants in the human body. So far, except for a few cases (e.g., the *SLCO1B1* genotype and statins pharmacokinetics/pharmacodynamics), there are still discrepancies in the results of functional confirmation (i.e., phenotype and genotype relationship), thus necessitating some concerns for further investigations.

Controversial and confused observations relating to the *in vivo* pharmacokinetic relevance of the polymorphisms of some drug transporter genes (e.g., *ABCB1* and *ABCG2*) may have arisen from the nonspecific substrate drugs used in the various studies. For example, in the *ABCB1* polymorphism, although digoxin and fexofenadine have been used as probed drugs for P-gp function, these are also known to be substrates, at least for polymorphic *SLCO1B3* and *SLCO1B1*, respectively.

Despite considerable effort, it is difficult to find specific substrates to corresponding specific transporters because the substrate specificity of most transporters is extremely broad and shows substantial overlap between different members of the superfamily. For this perspective, multiple gene analysis of the network of genes involved in drug metabolism, transport, and response (e.g., receptors), is preferable. For example, previous *in vitro* experiments reported that at least two transporters, but no cytochrome P450s, are involved in the pharmacokinetics of pitavastatin; OATP1B1 for uptake into hepatocytes and BCRP for efflux into the bile and gut lumen [190]. A pharmacogenomic human study of pitavastatin conducted with polymorphisms in *SLCO1B1* and *ABCG2* is of interest. Again, in order to establish a pharmacokinetic gene network, the integration of *in vitro* and animal experiments into the human study is essential.

Acknowledgements

This paper was supported by Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, and a grant from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.

Bibliography

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

1. CORDON-CARDO C, O'BRIEN JP, BOCCIA J, CASALS D, BERTINO JR, MELAMED MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. *J. Histochem. Cytochem.* (1990) 38:1277-1287.
2. THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I, WILLINGHAM MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc. Natl. Acad. Sci. USA* (1987) 84:7735-7738.
3. FOJO AT, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM, PASTAN I: Expression of a multidrug-resistance gene in human tumors and tissues. *Proc. Natl. Acad. Sci. USA* (1987) 84:265-269.
4. SUGAWARA I, KATAOKA I, MORISHITA Y *et al.*: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. *Cancer Res.* (1988) 48:1926-1929.
5. KIM RB, FROMM MF, WANDEL C *et al.*: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J. Clin. Invest.* (1998) 101:289-294.
6. MAYER U, WAGENAAR E, BEIJNEN JH *et al.*: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. *Br. J. Pharmacol.* (1996) 119:1038-1044.
7. NAKAMURA Y, IKEDA S, FURUKAWA T *et al.*: Function of P-glycoprotein expressed in placenta and mole. *Biochem. Biophys. Res. Commun.* (1997) 235:849-853.
8. SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J. Clin. Invest.* (1996) 97:2517-2524.
9. CORDON-CARDO C, O'BRIEN JP, CASALS D *et al.*: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc. Natl. Acad. Sci. USA* (1989) 86:695-698.
10. VAN DE WATER FM, MASEREUEW R, RUSSEL FG: Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. *Drug Metab. Rev.* (2005) 37:443-471.
11. SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. *Adv. Drug Deliv. Rev.* (2002) 54:1311-1331.
- This review describes the basic physiological and pharmacological functions of MRP2 and changes in the functions by genetic variations.
12. BUCHLER M, KONIG J, BROM M *et al.*: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. *J. Biol. Chem.* (1996) 271:15091-15098.
13. PAULUSMA CC, BOSMA PJ, ZAMAN GJ *et al.*: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. *Science* (1996) 271:1126-1128.
14. SCHAUB TP, KARTENBECK J, KONIG J *et al.*: Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. *J. Am. Soc. Nephrol.* (1999) 10:1159-1169.
15. MOTTINO AD, HOFFMAN T, JENNES L, VORE M: Expression and localization of multidrug resistant protein mpr2 in rat small intestine. *J. Pharmacol. Exp. Ther.* (2000) 293:717-723.
16. CERVENAK J, ANDRIKOVICS H, OZVEGY-LACZKA C *et al.*: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. *Cancer Lett.* (2006) 234:62-72.
17. MALIEPAARD M, SCHEFFER GL, FANEYTE IF *et al.*: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res.* (2001) 61:3458-3464.
18. KRUIJTZER CM, BEIJNEN JH, SCHELLENS JH: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. *Oncologist* (2002) 7:516-530.
19. TAIPALENSUU J, TORNBLOM H, LINDBERG G *et al.*: Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. *J. Pharmacol. Exp. Ther.* (2001) 299:164-170.
20. STAUD F, PAVEK P: Breast cancer resistance protein (BCRP/ABCG2). *Int. J. Biochem. Cell Biol.* (2005) 37:720-725.
21. XU J, LIU Y, YANG Y, BATES S, ZHANG JT: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. *J. Biol. Chem.* (2004) 279:19781-19789.
22. DOYLE AL, YANG W, ABRUZZO LV *et al.*: A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc. Natl. Acad. Sci. USA* (1998) 95:15665-15670.
23. KAGE K, TSUKAHARA S, SUGIYAMA T *et al.*: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. *Int. J. Cancer* (2002) 97:626-630.
24. ROSS DD: Novel mechanisms of drug resistance in leukemia. *Leukemia* (2000) 14:467-473.
25. KULLAK-UBLIICK GA, HAGENBUCH B, STIEGER B *et al.*: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. *Gastroenterology* (1995) 109:1274-1282.
26. SMITH LH, LEE W, KIM RB: Differential expression of OATP drug uptake transporters in human liver, intestine, and kidney. *Drug Metab. Rev.* (2003) 35:73.
27. DRESSER GK, KIM RB, BAILEY DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. *Clin. Pharmacol. Ther.* (2005) 77:170-177.
- This paper represents a new mechanistic insight into drug interaction.
28. TAMAI I, NEZU J, UCHINO H *et al.*: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. *Biochem. Biophys. Res. Commun.* (2000) 273:251-260.
29. ABE T, KAKYO M, TOKUI T *et al.*: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. *J. Biol. Chem.* (1999) 274:17159-17163.

30. HSIANG B, ZHU Y, WANG Z *et al.*: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J. Biol. Chem.* (1999) 274:37161-37168.
31. KONIG J, CUI Y, NIES AT, KEPPLER D: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. *J. Biol. Chem.* (2000) 275:23161-23168.
32. NOZAWA T, IMAI K, NEZU J, TSUJI A, TAMAI I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. *J. Pharmacol. Exp. Ther.* (2004) 308:438-445.
33. KULLAK-UBLICK GA, ISMAIR MG, STIEGER B *et al.*: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. *Gastroenterology* (2001) 120:525-533.
34. SEKINE T, WATANABE N, HOSYOYAMADA M, KANAI Y, ENDOU H: Expression cloning and characterization of a novel multispecific organic anion transporter. *J. Biol. Chem.* (1997) 272:18526-18529.
35. DRESSER MJ, LEABMAN MK, GIACOMINI KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. *J. Pharm. Sci.* (2001) 90:397-421.
36. MIYAZAKI H, SEKINE T, ENDOU H: The multispecific organic anion transporter family: properties and pharmacological significance. *Trends Pharmacol. Sci.* (2004) 25:654-662.
- This review describes the basic function of OATs in humans.
37. ENDOU H: Recent advances in molecular mechanisms of nephrotoxicity. *Toxicol. Lett.* (1998) 102-103:29-33.
38. CIHLAR T, LIN DC, PRITCHARD JB, FULLER MD, MENDEL DB, SWEET DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. *Mol. Pharmacol.* (1999) 56:570-580.
39. HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. *J. Am. Soc. Nephrol.* (2000) 11:383-393.
40. JARIYAWAT S, SEKINE T, TAKEDA M *et al.*: The interaction and transport of β -lactam antibiotics with the cloned rat renal organic anion transporter 1. *J. Pharmacol. Exp. Ther.* (1999) 290:672-677.
41. SIMONSON GD, VINCENT AC, ROBERG KJ, HUANG Y, IWANIJ V: Molecular cloning and characterization of a novel liver-specific transport protein. *J. Cell Sci.* (1994) 107:1065-1072.
42. SEKINE T, CHA SH, TSUDA M *et al.*: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. *FEBS Lett.* (1998) 429:179-182.
43. NAGATA Y, KUSUHARA H, ENDOU H, SUGIYAMA Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. *Mol. Pharmacol.* (2002) 61:982-988.
44. SWEET DH, MILLER DS, PRITCHARD JB, FUJIWARA Y, BEIER DR, NIGAM SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. *J. Biol. Chem.* (2002) 277:26934-26943.
45. JONKER JW, SCHINKEL AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). *J. Pharmacol. Exp. Ther.* (2004) 308:2-9.
46. BURCKHARDT G, WOLFRNA: Structure of renal organic anion and cation transporters. *Am. J. Physiol. Renal Physiol.* (2000) 278:F853-F866.
47. ZHANG L, DRESSER MJ, GRAY AT, YOST SC, TERASHITA S, GIACOMINI KM: Cloning and functional expression of a human liver organic cation transporter. *Mol. Pharmacol.* (1997) 51:913-921.
48. GORBOULEV V, ULZHEIMER JC, AKHOUNDOVA A *et al.*: Cloning and characterization of two human polyspecific organic cation transporters. *DNA Cell Biol.* (1997) 16:871-881.
49. VERHAAGH S, SCHWEIFER N, BARLOW DP, ZWART R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. *Genomics* (1999) 55:209-218.
50. SCHWAB M, EICHELBAUM M, FROMM MF: Genetic polymorphisms of the human MDR1 drug transporter. *Ann. Rev. Pharmacol. Toxicol.* (2003) 43:285-307.
- A comprehensive review of the *ABCB1* polymorphism.
51. FROMM MF: The influence of *MDR1* polymorphisms on P-glycoprotein expression and function in humans. *Adv. Drug Deliv. Rev.* (2002) 54:1295-1310.
52. KIM RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. *Drug Metab. Rev.* (2002) 34:47-54.
53. WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. *Mol. Carcinog.* (1995) 13:129-134.
54. KIM RB, WANDEL C, LEAKE B *et al.*: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. *Pharm. Res.* (1999) 16:408-414.
55. JEDLITSCHKY G, LEIER I, BUCHHOLZ U, BARNOUIN K, KURZ G, KEPPLER D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. *Cancer Res.* (1996) 56:988-994.
56. PRIEBE W, KRAWCZYK M, KUO MT, YAMANE Y, SAVARAJ N, ISHIKAWA T: Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. *Biochem. Biophys. Res. Commun.* (1998) 247:859-863.
57. BAKOS E, EVERS R, SINKO E, VARADI A, BORST P, SARKADI B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. *Mol. Pharmacol.* (2000) 57:760-768.
58. ISHIKAWA T: The ATP-dependent glutathione S-conjugate export pump. *Trends Biochem. Sci.* (1992) 17:463-468.
59. LOE DW, ALMQUIST KC, DEELEY RG, COLE SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. *J. Biol. Chem.* (1996) 271:9675-9682.